Vigmed granted additional patent in the US.

The US Patent and Trademark office has announced to Vigmed that it intends to grant the Company an additional patent for their needle protecting solution found in the product lines CLiP® and SWiTCH®.

Vigmed has earlier been granted patents for the needle protecting solution CLiP®, and systems comprising CLiP®. This patent will broaden Vigmed’s scope of protection, and additionally give the Company protection for another feature of CLiP® and SWiTCH®.

Vigmed has filed, nationally and internationally, more than 80 patents and patent applications based on more than three innovation platforms. The company owns all its patents and patent applications without any restrictions. The basic patents all have a maximum validity period.

Vigmed’s strategy is to protect the Company's technology and products in all geographical areas deemed to be of importance. Vigmed intends to expand its patent portfolio continuously on both the offensive and defensive patent and utility model rights based on a number of new innovation platforms.

For further information contact:

CEO Henrik Olsen, +46 42 600 5320 or R&D Director Fredrik Thörne, +46 42 600 5312

Vigmed är ett svenskt medicinteknologiskt bolag vars mission är att eliminera nålssticksskador och risken för smittspridning av farliga blodburna infektionssjukdomar genom att erbjuda marknaden unika nålskyddade stickprodukter. Vigmed har sitt huvudkontor i Helsingborg. Vigmeds aktie handlas på NASDAQ OMX First North under kortnamnet VIG och har cirka 5 600 aktieägare. Remium Nordic AB är bolagets Certified Advisor. Ytterligare information om bolaget återfinns på Vigmeds hemsida: www.vigmed.com/investor

Tags: